Skip to content
Sign in
DevelopingHealthPolicyScienceReported 2026-11-10 06:15

FDA Requires Vision Loss Warnings On Labels Of GLP-1 Medications

The FDA will require new warnings on labels of GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) linking them to non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, permanent vision loss, based on evidence from clinical trials and post-marketing reports.

Why it matters. Patients and healthcare providers must now be alert to a potential risk of acute vision loss associated with widely used diabetes and weight-loss medications, prompting monitoring for sudden vision changes.

01

Who and what it touches

FD&C ActrequiresActinium Pharmaceutic…regulatory exposure21 CFR 10.20regulated byexemption of class II…enablesNLCPpartners withOfficial Methods of A…uses21 CFR 862.9regulated by21 CFR 866.3385regulated byFDA

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • GGDELT Global Knowledge GraphMedia2026-11-10 06:15
    View source
  • CCNBC top newsMedia2026-11-10 16:22
    View source
  • TThe Guardian worldMedia2026-11-11 04:18
    View source
  • GGDELT Global Knowledge GraphMedia2026-11-11 19:30
    View source